Daniel Egle
Universitätsklinik für Frauenheilkunde und Geburtshilfe(AT)
Publications by Year
Research Areas
Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Advanced Breast Cancer Therapies, Cancer Treatment and Pharmacology, Cancer Genomics and Diagnostics
Most-Cited Works
- → Epigenetic stem cell signature in cancer(2006)1,147 cited
- → Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial(2015)552 cited
- → Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial(2017)379 cited
- → Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study(2022)369 cited
- → Spatial predictors of immunotherapy response in triple-negative breast cancer(2023)286 cited
- → Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study(2021)251 cited
- → Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial(2019)231 cited
- → Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer(2021)155 cited
- → Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry(2021)150 cited
- → Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study(2020)134 cited